| Literature DB >> 31875009 |
Lamya H Al-Wahaibi1, Jacques Joubert2, Olivier Blacque3, Nora H Al-Shaalan1, Ali A El-Emam4.
Abstract
5-(Adamantan-1-yl)-3-[(4-chlorobenzyl)sulfanyl]-4-methyl-4H-1,2,4-triazole (4) was identified as a potential 11β-hydroxysteroid deEntities:
Year: 2019 PMID: 31875009 PMCID: PMC6930263 DOI: 10.1038/s41598-019-56331-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The structures the adamanty l-1, 2, 4-triazoles (I–III) and related clinical 1, 2, 4-triazoles (IV–VI) 11β-HSD1 inhibitors.
Figure 2Synthetic approach for compound 4 (the percentage yields shown in parentheses are those obtained on carrying out the reaction in DMF with anhydrous potassium carbonate at room temperature).
Figure 3ORTEP diagram of the asymmetric unit of compound 4 drawn at 50% ellipsoids for non-hydrogen atoms.
Selected bond lengths (Å) and angles (°) of the crystal structure of compound 4.
| Bond | Length (Å) | Bond | Angle (°) |
|---|---|---|---|
| C1-C2 | 1.373(3) | C2-C1-Cl1 | 119.39(15) |
| C4-C7 | 1.505(3) | C5-C4-C7 | 119.51(19) |
| C7-S1 | 1.832(2) | C4-C7-S1 | 107.11(13) |
| C8-S1 | 1.752(17) | N1-C8-S1 | 125.05(13) |
| C8-N1 | 1.370(2) | N2-C8-N1 | 110.83(14) |
| C9-N3 | 1.316(2) | C9-C11-C12 | 111.98(13) |
| C10-N1 | 1.464(2) | C20-C18-C17 | 109.56(15) |
| N2-N3 | 1.380(2) | C8-N1-C9 | 104.71(13) |
| C9-C11 | 1.505(2) | C9-N2-N3 | 106.74(14) |
| C11-C19 | 1.546(2) | C9-N3-N2 | 108.40(13) |
| C15-C20 | 1.534(3) | C8-S1-C7 | 102.14(8) |
Figure 4(a) Molecular crystal packing showing the head-to-tail dimers of compound 4 within the unit cell. (b) Illustration showing the complex series of short-range intermolecular interactions (cyan) within the crystal field. The molecule shown in magenta was used as the central point to illustrate all interactions present. (c) Schematic of the prominent non-classical C-H…N hydrogen-bonds (red) observed, as described in Table 2.
Prominent hydrogen bonds for 4.
| D-H…A | d (H…A)/Å | d (D…A)/Å | (D-H…A)/° |
|---|---|---|---|
| C5-H5…N21 | 2.41 | 3.353 (2) | 175.6 |
| C10-H10C…N3i | 2.59 | 3.215 (2) | 121.9 |
Symmetry codes: (i) –x + 1, −y + 1, −z + 1.
Figure 5(a) The three-dimensional Hirshfeld surface showing the intermolecular interactions of 4 plotted over dnorm. (b) Electrostatic potential of 4 mapped using the 6-311 G(d,p) basis set at B3LYP level theory over a range ± 0.03 a.u. Dotted lines (green) signify prominent C-H…N hydrogen bonds.
Figure 6Fingerprint plots of 4, showing the contributions of atoms within specific interacting pairs (blue areas). For each fingerprint map, the grey area is a representation of the whole plot. Surface maps next to each fingerprint plot indicate the applicable areas (indicated in blue) that are associated with the specific intermolecular contact(s).
Figure 7Partial packing diagram showing the most prominent intermolecular interactions present within the crystal structure of 4 based on the Hirshfeld surface analysis findings. Interaction color scheme: H…H = Red; CH…N = Green; C…H = Magenta; Cl…H = Blue.
Figure 8Atom-by-atom superimposition of the DFT optimized compound (4a, magenta) on the X-ray structure (blue) of the title compound (RMSD = 1.491 Å, performed using YASARA version 18.11.21 (YASARA Biosciences GmbH)).
Selected torsion angles (Å) of the crystal structure and the DFT optimized structure (4a).
| Crystal structure | Crystal structure | DFT optimized structurea |
|---|---|---|
| Cl1-C1-C2-C3 | 179.12 | −179.92 |
| C3-C4-C7-S1 | −85.68 | −87.33 |
| C4-C7-S1-C8 | 179.33 | 169.53 |
| N2-C8-N1-C10 | −177.78 | 177.56 |
| S1-C8-N1-C9 | 177.28 | 175.58 |
| S1-C8-N2-N3 | −177.37 | −174.80 |
| N1-C8-S1-C7 | 82.82 | −147.06 |
| N3-C9-C11-C12 | 126.1 | 98.62 |
| C11-C9-N1-C8 | 179.65 | −178.58 |
| N3-C9-N1-C10 | 177.85 | −177.99 |
| C9-C11-C12-C13 | −178.43 | −178.64 |
| C19-C11-C12-C13 | −59.54 | −59.24 |
aThe B3LYP/6-311++G(d,p) level of theory was used for optimization.
Figure 9The HOMO and LUMO FMOs of conformer 4a calculated using B3LYP/6-311++G (d,p).
Figure 10The net atomic charges (e) of the DFT optimized structure of compound 4.
Figure 11The binding mode, orientation and predicted binding affinity (kcal/mol) of 4YQ (magenta) and 4a (green) within the 11β-HSD1 active site.
Figure 12Binding interactions of the co-crystallized ligand, 4YQ (left) and conformer 4a (right), within the 11β-HSD1 active site.
Single crystal X-ray crystallographic data of 4.
| Data | Compound 4 |
|---|---|
| Formula | C20H24ClN3S |
| Formula weight | 373.93 |
| Temperature (K) | 160 |
| Crystal system, Space group | Monoclinic, |
| 6.61380(10), 13.3456(2), 20.9061(4) | |
| ß (°) | 96.361(1) |
| V (Å3) | 1833.92(5) |
| 4 | |
| Radiation type | CuKα (λ = 1.54184) |
| 2.954 | |
| No. of reflections | 13268 |
| No. of unique reflections/obs. reflections | 3708/3107 |
| No. of parameters | 227 |
| No. of restraints | 0 |
| Δρmax, Δρmin (e Å−3) | +0.39, −0.39 |
| 0.706, 0.875 | |
| 0.0353 | |
| Crystal size (mm) | 0.18 × 0.08 × 0.05 |
| R[ | 0.0379, 0.0865, 1.020 |
| CCDC number | 1918378 |